Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Study to Evaluate the Effect of Every Other Week PROCRIT� (Epoetin Alfa) Dosing (40,000-60,000 Units) On Maintaining Quality of Life and Target Hemoglobin Levels in Anemic HIV-Infected Patients (CHAMPS II)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Understand and sign written informed consent~* HIV-infected patients (as documented by HIV-RNA values)~* HIV/HCV co-infected patients not receiving treatment~* Hemoglobin \< 12 g/dL unrelated to transfusion~* Estimated life expectancy of \> 9 months~* Has been maintained on a stable antiretroviral regimen for at least four weeks prior to enrollment into this study.~Exclusion Criteria:~* Acute, symptomatic opportunistic infection or other acute AIDS defining illness~* Anemia attributable to factors other than HIV infection (i.e., iron, B12 or folate deficiencies, hemolysis, gastrointestinal bleeding)~* HCV co-infected patients who are anticipated to receive treatment with ribavirin/interferon during the study period. Previous treatment with ribavirin/interferon must have been completed at least 12 weeks prior to study entry~* Ferritin level \< 40 ng/mL~* Uncontrolled or severe cardiovascular disease including recent (\< 6 months) myocardial infarction, uncontrolled hypertension or congestive heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).